Financhill
Back

Amneal Pharmaceuticals Quote, Financials, Valuation and Earnings

Amneal Pharmaceuticals Price Quote

$8.40
+0.01 (+0.96%)
(Updated: November 23, 2024 at 5:25 AM ET)

Amneal Pharmaceuticals Key Stats

Buy
55
Amneal Pharmaceuticals (AMRX) is a Buy

Day range:
$8.25 - $8.43
52-week range:
$4.16 - $9.48
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.92
P/B ratio:
0%

Volume:
794K
Avg. volume:
1M
1-year change:
88.54%
Market cap:
$2.6B
Revenue:
$2.4B
EPS:
$-0.68

How Much Does Amneal Pharmaceuticals Make?

Is Amneal Pharmaceuticals Growing As A Company?

Amneal Pharmaceuticals Stock Price Performance

What Is Amneal Pharmaceuticals 52-Week High & Low?

Amneal Pharmaceuticals Price To Free Cash Flow

Is It Risky To Buy Amneal Pharmaceuticals?

Is Amneal Pharmaceuticals Cash Flow Positive?

  • What Is AMRX Cash Flow From Operations?
    Cash flow from operations (TTM) is $312.8M
  • What Is Amneal Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$251.4M
  • What Is Amneal Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$78.6M

Amneal Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    AMRX return on invested capital is -6.95%
  • What Is Amneal Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -5.24%
  • What Is AMRX Return On Equity?
    ROE is a measure of profitability and is -587.3%

Amneal Pharmaceuticals Earnings Date & Stock Price

Amneal Pharmaceuticals Competitors

Amneal Pharmaceuticals Dividend Yield

Amneal Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 18.3%
Revenue: 13.29% 1.26%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 10.50
Upside from Last Price: 25.15%

Major Shareholders

  • How many AMRX shares are owned by institutional investors?
    182M AMRX shares are owned by institutional investors
  • How many AMRX shares are owned by insiders?
    7.5M AMRX shares are owned by insiders